Silymarin alleviates diclofenac-induced hepatotoxicity in male Wistar rats: Histopathological investigation

Background: One of the primary concerns of the pharmaceutical industry is the potential for liver damage caused by drugs. Diclofenac is a member of the family ofnonsteroidall antiinflammatory medications (NSAIDs), which are known for their anti-inflammatory, antipyretic, and analgesic effects. Alth...

Full description

Saved in:
Bibliographic Details
Main Author: Fawiziah Khalaf Alharbi
Format: Article
Language:English
Published: Tripoli University 2025-04-01
Series:Open Veterinary Journal
Subjects:
Online Access:http://www.ejmanager.com/fulltextpdf.php?mno=247108
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849312191040192512
author Fawiziah Khalaf Alharbi
author_facet Fawiziah Khalaf Alharbi
author_sort Fawiziah Khalaf Alharbi
collection DOAJ
description Background: One of the primary concerns of the pharmaceutical industry is the potential for liver damage caused by drugs. Diclofenac is a member of the family ofnonsteroidall antiinflammatory medications (NSAIDs), which are known for their anti-inflammatory, antipyretic, and analgesic effects. Although it is commonly prescribed, liver damage is one of the primary risks associated with this medication. Therefore, it is necessary to use a prospective therapeutic medication that can counteract the cytotoxic impact of diclofenac. Humans have utilized natural items as a means of obtaining sustenance, maintaining their health, and treating a wide variety of illnesses. Antioxidant, anti-inflammatory, and liver-protective properties are associated with silymarin, which is a flavonoid chemical derived from the seeds of the Silybum marianum plant. Aim: This study aimed to evaluate the possible hepatoprotective effect of silymarin against diclofenac-induced liver injury. Methods: Forty Wistar rats were used in the current investigation and grouped randomly into four equal groups. The first group (G1) was kept as a control group. G2 received intraperitoneal injections of diclofenac (50 mg/kg. BW/day) for 5 days. G3 received oral silymarin for 5 days (200 mg/kg BW/day) dissolved in distal water. G4 received diclofenac plus silymarin with the same previously mentioned doses for 5 days. The animals were collected and subjected to histopathological examination. Results: The diclofenac-treated group showed several pathological changes within the hepatic parenchyma, including diffuse coagulative and hydropic degenerations with general disorganization of the hepatic cords, severe dilatation and congestion of the central vein and portal blood vessels, severe sinusoidal dilatation and congestions accompanied with severe pressure atrophy of the hepatic cords, and severe inflammatory cell infiltrations. Meanwhile, the diclofenac plus silymarin-treated group showed a significant good effect, where silymarin ameliorated almost all histopathological lesions induced after diclofenac treatment as mitigating the degenerative changes of hepatocytes, minimizing inflammatory cell infiltrations, and normal organized hepatic rays with normal sinusoids in between were distinguished. Conclusion: Silymarin has a significant hepatoprotective effect against diclofenac-induced hepatotoxicity through neutralization of all histopathological injuries. [Open Vet J 2025; 15(4.000): 1790-1797]
format Article
id doaj-art-9dac50097fb74434a8ce924ef1fea724
institution Kabale University
issn 2226-4485
2218-6050
language English
publishDate 2025-04-01
publisher Tripoli University
record_format Article
series Open Veterinary Journal
spelling doaj-art-9dac50097fb74434a8ce924ef1fea7242025-08-20T03:53:08ZengTripoli UniversityOpen Veterinary Journal2226-44852218-60502025-04-011541790179710.5455/OVJ.2025.v15.i4.31247108Silymarin alleviates diclofenac-induced hepatotoxicity in male Wistar rats: Histopathological investigationFawiziah Khalaf Alharbi0Department of Biology, College of Science, Buraydah, Qassim University, Buraydah, Saudi Arabia.Background: One of the primary concerns of the pharmaceutical industry is the potential for liver damage caused by drugs. Diclofenac is a member of the family ofnonsteroidall antiinflammatory medications (NSAIDs), which are known for their anti-inflammatory, antipyretic, and analgesic effects. Although it is commonly prescribed, liver damage is one of the primary risks associated with this medication. Therefore, it is necessary to use a prospective therapeutic medication that can counteract the cytotoxic impact of diclofenac. Humans have utilized natural items as a means of obtaining sustenance, maintaining their health, and treating a wide variety of illnesses. Antioxidant, anti-inflammatory, and liver-protective properties are associated with silymarin, which is a flavonoid chemical derived from the seeds of the Silybum marianum plant. Aim: This study aimed to evaluate the possible hepatoprotective effect of silymarin against diclofenac-induced liver injury. Methods: Forty Wistar rats were used in the current investigation and grouped randomly into four equal groups. The first group (G1) was kept as a control group. G2 received intraperitoneal injections of diclofenac (50 mg/kg. BW/day) for 5 days. G3 received oral silymarin for 5 days (200 mg/kg BW/day) dissolved in distal water. G4 received diclofenac plus silymarin with the same previously mentioned doses for 5 days. The animals were collected and subjected to histopathological examination. Results: The diclofenac-treated group showed several pathological changes within the hepatic parenchyma, including diffuse coagulative and hydropic degenerations with general disorganization of the hepatic cords, severe dilatation and congestion of the central vein and portal blood vessels, severe sinusoidal dilatation and congestions accompanied with severe pressure atrophy of the hepatic cords, and severe inflammatory cell infiltrations. Meanwhile, the diclofenac plus silymarin-treated group showed a significant good effect, where silymarin ameliorated almost all histopathological lesions induced after diclofenac treatment as mitigating the degenerative changes of hepatocytes, minimizing inflammatory cell infiltrations, and normal organized hepatic rays with normal sinusoids in between were distinguished. Conclusion: Silymarin has a significant hepatoprotective effect against diclofenac-induced hepatotoxicity through neutralization of all histopathological injuries. [Open Vet J 2025; 15(4.000): 1790-1797]http://www.ejmanager.com/fulltextpdf.php?mno=247108silymarindiclofenachepatotoxicityhepatoprotectivehistopathological
spellingShingle Fawiziah Khalaf Alharbi
Silymarin alleviates diclofenac-induced hepatotoxicity in male Wistar rats: Histopathological investigation
Open Veterinary Journal
silymarin
diclofenac
hepatotoxicity
hepatoprotective
histopathological
title Silymarin alleviates diclofenac-induced hepatotoxicity in male Wistar rats: Histopathological investigation
title_full Silymarin alleviates diclofenac-induced hepatotoxicity in male Wistar rats: Histopathological investigation
title_fullStr Silymarin alleviates diclofenac-induced hepatotoxicity in male Wistar rats: Histopathological investigation
title_full_unstemmed Silymarin alleviates diclofenac-induced hepatotoxicity in male Wistar rats: Histopathological investigation
title_short Silymarin alleviates diclofenac-induced hepatotoxicity in male Wistar rats: Histopathological investigation
title_sort silymarin alleviates diclofenac induced hepatotoxicity in male wistar rats histopathological investigation
topic silymarin
diclofenac
hepatotoxicity
hepatoprotective
histopathological
url http://www.ejmanager.com/fulltextpdf.php?mno=247108
work_keys_str_mv AT fawiziahkhalafalharbi silymarinalleviatesdiclofenacinducedhepatotoxicityinmalewistarratshistopathologicalinvestigation